# Special Issue

# Advances in the Use of Nanoparticles for Vaccine Platform Development: 2nd Edition

## Message from the Guest Editor

Vaccination is effective in preventing diseases. New vaccine candidates have been developed, including nucleic acids and subunit vaccines. These innovations have led to vaccines that induce specific immune responses with fewer side effects. However, newer-generation vaccines sometimes show lower immunogenicity. Nanoparticle-based formulations enhance immune responses. These systems protect vaccine candidates, improve stability, and have adjuvant properties. They target antigen-presenting cells and can elicit immune responses, with flexibility for various administration routes. Manufacturing methods are advancing. This Special Issue invites original research and review articles focusing on the preclinical and clinical development of advanced nanoparticle delivery systems. These may include liposomes; lipid-based, polymeric, gold, inorganic, and biomimetic nanoparticles; virus-like particles; self-assembled proteins; and other forms, including carbon-based nanoparticles such as carbon nanotubes and graphene.

## Guest Editor

Prof. Dr. Imran Saleem

School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Liverpool L3 3AF, UK

## Deadline for manuscript submissions

31 May 2026

**Vaccines**

**an Open Access Journal by MDPI**

**Impact Factor 3.4**
**CiteScore 9.9**
**Indexed in PubMed**

mdpi.com/si/231911

*Vaccines*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

mdpi.com/journal/vaccines

# Vaccines

an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed

mdpi.com/journal/vaccines

# About the Journal

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

## Editor-in-Chief

Prof. Dr. Ger Rijkers
Department of Health, Cognition and Behavior, University College Roosevelt, 4331 CB Middelburg, The Netherlands

## Author Benefits

**High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:**

JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

**Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).

MDPI